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Abstract
Background: In recent years, the impact of antituberculous treatment on interferon (IFN)-c response to Mycobacterium
tuberculosis antigens has been widely investigated, but the results have been controversial. The objective of the present
study was: i) to evaluate longitudinal changes of IFN-c response to M. tuberculosis-specific antigens in TB patients during
antituberculous treatment by using the QuantiFERON-TB Gold (QFT-G) assay; ii) to compare the differences in T-cell
response after a short or prolonged period of stimulation with mycobacterial antigens; iii) to assess the CD4+ and CD8+ T
cells with effector/memory and central/memory phenotype; iv) to investigate the direct in vitro effects of antituberculous
drugs on the secretion of IFN-c.
Principal Findings: 38 TB patients was evaluated at baseline and at month 2 and 4 of treatment and at month 6 (treatment
completion). 27 (71%) patients had a QFT-G reversion (positive to negative) at the end of therapy, while 11 (29%) TB
patients remained QFT-G positive at the end of therapy. Among the 11 patients with persistent positive QFT-G results, six
had a complete response to the treatment, while the remaining 5 patients did not have a resolution of the disease. All 27
patients who became QFT-G negative had a complete clinical and microbiological recovery of the TB disease. In these
patients the release of IFN-c is absent even after a prolonged 6-day incubation with both ESAT-6 and CFP-10 antigens and
the percentage of effector/memory T-cells phenotype was markedly lower than subjects with persistent positive QFT-G
results. The in vitro study showed that antituberculous drugs did not exert any inhibitory effect on IFN-c production within
the range of therapeutically achievable concentrations.
Conclusions: The present study suggests that the decrease in the M. tuberculosis-specific T cells responses following
successful anti-TB therapy may have a clinical value as a supplemental tool for the monitoring of the efficacy of
pharmacologic intervention for active TB. In addition, the antituberculous drugs do not have any direct down-regulatory
effect on the specific IFN-c response.
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Introduction
The immunologic and clinical relevance of measuring T cell
response to Mycobacterium tuberculosis infection has been highlighted
in a wide number of studies. In particular, the development and
introduction in clinical practice of the interferon-gamma release
assays (IGRAs) has open new perspectives for the detection of
tuberculosis (TB) infection [1–5]. These assays detect cellular
immune response by measuring interferon-gamma (IFN-c)
released by T cells after stimulation by M. tuberculosis antigens,
such as early secreted antigen target (ESAT)-6 and culture filtrate
protein (CFP)-10. These proteins, encoded by genes located within
the region of difference 1 (RD1) segment of the M. tuberculosis
genome, are highly specific for M. tuberculosis and are secreted by
metabolically active and viable bacilli [6–7]. The IFN-c assay has
several advantages over tuberculin skin test (TST), in terms of
higher specificity and better correlation with surrogate measures of
exposure to M. tuberculosis in low-incidence setting, and less cross-
reactivity with M. bovis Bacille Calmette Guerin (BCG) vaccine
strains and environmental mycobacteria [8–14].
Despite the growing body of evidence supporting the routinely
use of IFN-c-based tests in clinical practice, there are important
issues that need to be thoroughly investigated. In particular, it
remains to be clarified the dynamics of specific T-cell responses
with the use of IGRAs in patients with active TB before, during,
and after antituberculosis treatment. The impact on the IFN-c
responses of antituberculous treatment has been previously
examined, but the results have been controversial. In fact, some
studies have shown decreasing or negative responses [15–19],
while others described increased or persistently positive responses
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responses is influenced by various factors, including assay
characteristics, antigen load in different stage of the disease and
the functional diversity of T-cell response. It has been suggested
that the short period of incubation (16–24 hours) commonly used
in IGRAs detect responses of activated effector T cells that rapidly
release IFN-c when stimulated in vitro with antigen [15,17,26–
28]. By contrast, long-lived central memory T cells may be less
likely to release IFN-c during the short period of exposure to
antigen in the IGRA assay, while they could be detected after a
longer period of in vitro stimulation [29–30]. Since the effector
response is driven by the antigen load, it is thought that in the
presence of active mycobacterial replication (active untreated TB),
the numbers of effector T cells are increased. In the context of a
low antigenic load, as in successfully treated patients, the number
of effector cells specific to M. tuberculosis antigen could fall below
the cut-off level [27]. To date, it is unclear if IGRAs may serve as
surrogate markers of mycobacterial burden that could be useful for
the monitoring of the response to anti-TB treatment.
In this study, we evaluated longitudinal changes of IFN-c
response to M. tuberculosis-specific antigens in TB patients during
the standard antituberculous treatment by using the Quanti-
FERON-TB Gold (QFT-G) assay, a commercial IGRA common-
ly used in clinical practice. The results of QFT-G test were
correlated with microbiologic and clinical outcome. Furthermore,
to better define the dynamic of immunologic response at the end of
treatment, a whole blood IGRA was used to compare IFN-c
secretion after an overnight and a 6-day incubation with
mycobacterial recombinant RD1 proteins, respectively. Finally,
the impact of the anti-TB treatment on QFT-G result was also
evaluated by assessing the direct in vitro effects of antituberculous
drugs on the secretion of IFN-c.
Materials and Methods
Study population
The study population included 38 patients with active TB,
admitted to the Department of Infectious and Tropical Diseases of
the Sapienza University of Rome, Italy. Twenty-six patients had
pulmonary TB, while twelve were affected by extrapulmonary
disease (three lymphadenitis, one meningitis, four vertebral TB,
two disseminated TB and two peritoneal TB). Diagnosis of TB was
made on the basis of clinical and radiological findings and was
confirmed by identification of M. tuberculosis with microbiological
methods and/or histological examination of affected tissues. All
patients were treated with the four classical antituberculous drugs
(rifampicin, isoniazid, pyrazinamide and ethambutol). The control
group included 16 healthy unexposed individuals with no history
of TB in the past, and no know TB contact. All patients were
seronegative for HIV infection. Baseline information for all
patients is shown in Table 1. For each enrolled participant venous
blood samples were collected in heparin-containing tubes at the
time of diagnosis, 2 and 4 months after the beginning of treatment
and at completion of specific treatment (6 months). Patients were
classified as ‘responders to treatment’ if, after 6 months of specific
therapy, the results of microbiological cultures in appropriate
specimens were negative for M. tuberculosis and there was a clinical
and radiological improvement associated with normal inflamma-
tory parameters (C-reactive protein concentration and sedimen-
tation rate). Drug susceptibility testing for rifampicin and isoniazid
was performed using the Genotype MTBDR assay (Hain
Lifescience, Nehren, Germany). The control group was sampled
3 times at corresponding intervals (every 15 days). The study was
approved by the institutional review board (Department of
Infectious and Tropical Diseases, Sapienza University of Rome)
and informed written consent was obtained before blood donation.
Commercial QuantiFERON-TB Gold (Cellestis Limited,
Australia)
The QFT-G was performed according to the manufacturer’s
instructions. Briefly, a blood samples was draw into heparin tubes,
and within 2–6 hours of blood draw, four aliquots of 1 ml of
heparinized blood were incubated overnight in wells of a plate at
37uC in a humidified atmosphere in the presence of 3 drops of
negative control (saline), mitogen positive control (phytohemag-
glutinin) and two M. tuberculosis-specific antigens: ESAT-6 and
CFP-10 (overlapping peptides). After 24 hours incubation, plasma
aliquots were harvested, and frozen at 70uC, until the assay was
performed. The amount of IFN-c released (IU/ml) was deter-
mined using enzyme-linked immunosorbent assay (ELISA).
For each subject, the negative control value was subtracted from
the values of antigen-stimulated plasma samples. The cut-off value
for a positive response was set at 0.35 IU/ml for ESAT-6 and
CFP-10, while for a negative response the concentration of IFN-c
in both antigen wells was less than 0.35 UI/ml and concentration
in the positive-control well was 0.5 UI/ml or more. The QFT-G
test result was considered indeterminate if the concentration of
IFN-c was less than 0.35 UI/ml in both antigens well and less than
0.5 UI/ml in the positive-control well, or if the concentration of
IFN-c in the negative well is higher than 8.0 UI/ml. Analysis of
data was done by the QuantiFERON-TB Gold Analysis Software.
Detection of IFN-c release after overnight and a 6-day
incubation with mycobacterial antigens
The production of IFN-c release after overnight and a 6-day
incubation with mycobacterial antigens was performed using a
whole blood IGRA. Heparinized blood was diluted 1 in 5 with
serum-free medium (RPMI supplemented with penicillin and
streptomycin plus 2 mM L-glutamine) and 250 mL was seeded in a
well plate and were stimulated with following stimuli: i) intact
recombinant (r)ESAT-6 protein (Lionex, Germany: purity .95%;
Table 1. Baseline characteristics of the subjects included in
the study.
Characteristics
Patients with active
TB (n=38)
Healthy control
subjects (n=16)
Age (range, years) 15–78 20–65
Sex
Male 18 9
Female 20 7
Place of birth
Italy 20 16
Africa 8 0
Eastern Europe 6 0
Asia 4 0
BCG vaccination 10 0
Active TB
Pulmonary disease 26 0
Extrapulmonary disease 12 0
Abbreviations:
BCG: Bacillus Calmette and Guerin; TB: tuberculosis.
doi:10.1371/journal.pone.0005187.t001
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PLoS ONE | www.plosone.org 2 April 2009 | Volume 4 | Issue 4 | e5187endotoxin content: 655 EU/mg;) at 1 mg/mL and (r)CFP-10
protein (Lionex, Germany: purity .95%; endotoxin content:
9,8 EU/mg;) at 0.5 mg/ml; ii) purified protein derivative (PPD;
batch RT47; Statens Serum Institute) at 5 mg/mL; iii) phytohe-
magglutinin (PHA) (Sigma, St Louis, MO, USA) at 5 mg/mL as
positive control; iv) medium alone as negative control. The
samples were incubated on the day of blood collection at 37uC
with 5% CO2. Supernatants were harvested after overnight and 6-
day incubation and then were immediately tested for IFN-c by
using a commercial ELISA, according to the manufacturer’s
instructions (QuantiFERON-CMI, Cellestis Ltd, Carnegie, Vic-
toria, Australia). IFN-c concentrations were expressed as IU/ml,
and the negative control value was subtracted from the values of
antigen-stimulated plasma samples.
Phenotypic analysis by flow cytometry
Phenotypic analysis of CD4+ and CD8+ T cells was performed
by flow-cytometric analysis, analyzing expression of the memory
markers such as CD45RO and CCR7.
Heparinized whole blood was diluted, stimulated and incubated
as described above. After 6 days of incubation, supernatants were
recovered and the cells were harvested by washing the wells with
300 ml of PBS. The following monoclonal antibodies (mAbs) were
added: anti-CD4-peridinim chlorophyll (PerCP); anti-CD8-peri-
dinim chlorophyll (PerCP); anti-CD45RO-allophycocyanine
(APC); anti-CD3-fluorescein isothiocyanate (FITC), and anti-
CCR7-phycoerythrin (PE). All mAbs were purchased from Becton
Dickinson (BD Biosciences Pharmigen, Italy). The cells were
incubated for 20 minutes in the dark at room temperature (RT);
1 ml of FACS Lysing Solution (BD) was added, vortexed and
incubated for 15 minutes at RT. Samples were analyzed within
1 h of the staining using a FACSCalibur flow cytometer and
CellQuest software version 1.0 (Becton Dickinson, Mountain
View, CA, USA). All data were collected using identical
instrument settings.
We defined an R1 gate for lymphocytes in a dot plot of Forward
Scatter Chanel (FSC) versus Side Scatter Chanel (SSC). To identify
CD4+ and CD8+ T cells, events from R1 were analyzed in a plot
of CD3-FITC vs CD4-PerCP or CD8-PerCP respectively (R2).
Finally, gated CD4+ and CD8+ T cells were analyzed for CCR7-
PE vs CD45RO-APC.
Data are reported as percentages of CD4+ and CD8+ T cells
with both an effector/memory (EM) phenotype, defined as
CD45RO+/CCR72, and central/memory (CM) phenotype,
characterized by the CD45RO+/CCR7+.
In vitro effect of antituberculous drugs on the IFN-c
release
The in vitro effect of the combination of rifampicin (RIF)/
isoniazid (INH)/pyrazinamide (PZA)/ethambutol (ETB) (Becton
Dickinson) on the IFN-c release was performed as follows.
Aliquots of 0,5 ml of heparinized blood were incubated overnight
at 37uC, with 5% CO2, in the presence of PHA (5 mg/mL) or a
solution of the 4 antituberculous drugs at three different
concentrations. On the basis of therapeutically achievable
concentrations, the first concentration (C1) of combined drugs
was: INH 5 mg/ml, RIF 7 mg/ml, ETB 5 mg/ml, PZA 40 mg/ml.
The other concentrations were two (C2) or three (C3) times
greater. All conditions were set up in triplicate wells. Positive
control wells contained only PHA at 5 mg/ml. The IFN–c release
(expressed as IU/ml) in the presence or absence of the drug, was
assessed by ELISA, using a commercial kit, according to the
manufacturer’s recommendations (QuantiFERON-CMI, Cellestis
Ltd, Carnegie, Victoria, Australia). Cellular vitality was assessed
with trypan blue.
Statistical analysis
SPSS version 13.0 for windows (SPSS Inc., Apache Software
Foundation, Chicago, Illinois) was used. The differences of values
between the different groups were analysed using the non-
parametric Mann-Whitney U-test. Data in the longitudinal
analysis during the treatment course of individual patients were
evaluated with the non parametric Wilcoxon signed-rank test (two
tailed). Student’s t test was used for statistical analysis of data from
in vitro experiments with antituberculous drugs. P–value ,0,05
was regarded as significant.
Results
Changes in the T-cell IFN-c response to M. tuberculosis
antigens during anti-TB therapy by QFT-G assay
Thirty eight patients with confirmed TB were followed up
longitudinally and tested with QFT-G at the time of diagnosis, 2
and 4 months after the beginning of treatment and at completion
of specific treatment (6 months).
At baseline all 38 patients had positive QFT-G responses. After
the beginning of anti-TB treatment, QFT-G assay was positive in
31/38 (81.5%) patients at month 2 and in 22/38 (57.8%) patients
at month 4. At the end of therapy a reversion to negative response
was found in 27/38 (71%) of patients, while 11/38 (29%) patients
remained QFT-G positive.
The individual change of IFN-c response to sum of ESAT-6 and
CFP-10 peptides during the treatment for each participant is
shown in Figure 1. Taken together, the data showed a significant
decrease in average IFN-c response in all 38 TB patients during
the follow-up (p,0.001). The median of IFN-c concentrations in
the 27 patients who became QFT-G negative throughout the 6
months of treatment and in the 11 patients who remained
persistently QFT-G positive on treatment completion was
reported in Table 2. The results showed that there was a
significant decrease in IFN-c concentrations in TB patients who
became QFT-G negative at the end of treatment (p,0.001). By
contrast, after an initial decline, the concentrations of IFN-c did
not show significant changes in patients who remained QFT-G
positive on treatment completion (p=0,085). No significant
differences were seen in the baseline IFN-c concentrations
between the two groups of patients (p=0,215).
All patients who showed a significant decline in IFN-c
concentrations and became QFT-G negative after treatment had
a complete clinical and microbiological recovery of the TB disease.
Among the 11 patients with persistent positive QFT-G results, 6
patients were considered as ‘responders to treatment’ on the basis
of clinical, radiological, microbiological and laboratory findings;
the remaining 5 patients, who had persistent culture positive
samples after 2 months, did not have a complete resolution of the
clinical disease and early relapsed after the 6-month treatment
completion (Table 3).
To determine whether the changes in response to specific
antigens were indicative of M. tuberculosis–specific immunity and
not the result of generalized fluctuations in T-cell response, we also
carried out a longitudinal analysis in 16 healthy controls. There
was no significant variations in IFN-c concentrations during
longitudinal QFT-G testing at 3 different intervals of time (every
15 days) [median IFN-c (range): 0.01 UI/mL (0–0.11); 0.01 UI/
mL (0.1–0.13); 0.015 UI/mL (0–0.1); p=0,664]. Thus, this group
of healthy unexposed individuals with no history of TB and no
Anti-TB Drugs and IFN-c Assay
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below the detection threshold of the ex vivo QFT-G.
IFN-c production in response to M. tuberculosis antigens
using different incubation times
The differences in T-cell response after a short or prolonged
period of stimulation with mycobacterial antigens was investigated
in a subset of 8 TB patients who had a QFT-G reversion (positive
to negative) after completion of treatment and in 10 TB subjects
who remained QFT-G positive at the end of therapy. IFN-c
concentrations in response to sum of rRD1 proteins (rESAT-6 and
rCFP-10), PPD and PHA were measured after overnight and 6-
day incubation by a whole blood IGRA (Table 4).
In the 8 patients who became QFT-G negative at the end the
treatment, no significant differences in immunologic response were
found between short and longer incubation with rRD1 antigens
(p=0,625). Indeed, also the prolonged 6-day in vitro stimulation
with rRD1 antigens failed to evoke IFN-c production, while there
was an increased response to PPD (p=0.03 versus overnight
incubation).
By contrast, in the 10 TB patients who remained QFT-G
positive after the treatment, a response to all the antigens used was
found both after a short and a longer period of stimulation in vitro.
The results confirmed that the immune response to each antigens
after 6-day incubation was statistically higher compared to
overnight stimulation (p=0,004 for rRD1 and p=0,005 for
PPD) (Table 4). IFN-c responses to recombinant RD1 proteins
after 18 h of stimulation in whole blood IGRA did not differ
significantly from those generated with a pool of overlapping
peptides used in QFT-G assay (p=0,733 for ESAT-6 and
p=0,809 for CFP-10 (data not shown).
No significant increase in IFN-c concentrations was observed in
5 healthy controls in response to any antigens after stimulation of 6
days, although a positive response to the mitogen PHA was
detectable (p=0.211 for rRD1 and p=0.078 for PPD) (Table 4).
In summary, our results showed that the increase in IFN-c
production in response to rRD1 proteins after 6 days of
stimulation was entirely restricted to the TB patients with
persistent positive QFT-G results (Figure 2).
Phenotypic analysis of CD4+ and CD8+ T cells
The cytofluorimetric analysis of the phenotypic profile of CD4+
and CD8+ T cells in the 10 patients with persistent QFT-G
positive results and in the 8 individuals who showed a QFT-G
reversion (positive to negative) at the end of treatment is reported
in Table 5. In the patients with positive QFT-G results at the end
Figure 1. Longitudinal changes of specific IFN-c response in 38 TB patients following anti-tuberculous treatment. IFN-c response to
sum of ESAT-6 and CFP-10 (overlapping peptides) was measured by QFT-G before, during and at the end of treatment. A significant decrease of IFN-c
response to mycobacterial antigens was found during the therapy (p,0.001, Wilcoxon’s signed-rank test). [p: for the comparison of the results at
baseline vs. completion of therapy]. Horizontal black line indicates the QFT-G assay cut-off value for a positive result (0.35 UI/mL).
doi:10.1371/journal.pone.0005187.g001
Table 2. IFN-c concentrations in TB patients according to the results of QFT-G assay at the end of treatment.
Patients Median IFN-c release in UI/mL (range) P value
0 months 2 months 4 months 6 months
Group A (n=27)
ESAT-6/CFP-10 2,79 (0,41–19,29) 0,82 (0–27,67) 0,21 (0–6,22) 0,02 (0–0,3) ,0,001
Group B (n=11)
ESAT-6/CFP-10 3,63 (1,44–15,77) 2,1 (0,82–27,67) 4 (0,4–9,05) 3,25 (0,68–7) 0,085
Group A: TB patients who had a QFT-G reversion (positive to negative) at the end of therapy.
Group B: TB patients who remained QFT-G positive at the end of therapy.
doi:10.1371/journal.pone.0005187.t002
Anti-TB Drugs and IFN-c Assay
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memory (EM) and central memory (CM) phenotype after 6 days of
rRD1 antigen-specific in vitro stimulation was significantly higher
than that seen in subjects who showed a QFT-G reversion
(p=0.001 and p=0.003, respectively).
Similarly, the percentage of CD8+T-cells with EM phenotype
was significantly higher in patients with positive QFT-G results
than in those with negative QFT-G results (p=0.036 for EM). No
significant difference was observed in the percentage of CD8+ T-
cells with CM phenotype among two groups of patients (p=0.087)
(Table 5). The cytofluorimetric analysis from a representative TB
patient with QFT-G reversion (positive to negative) and a patient
with persistent QFT-G positive after treatment is shown in
Figure 3.
In vitro effect of antituberculous drugs on IFN–c release
To determine whether antituberculous drugs had an inhibitory
effect on the IFN-c release by T cells, the heparinized blood
samples were incubated in vitro with a combination of INH, RIF,
ETB, STR. The concentrations of IFN-c (mean6SE, UI/ml)
measured at the three different used concentrations were as
follows: C1, 3.76760.18; C2, 1.8560.21; C3, 0.66760.286
(Figure 4). IFN-c release was inhibited in a dose-dependent
manner. It is important to point out that a significant inhibitory
effect was seen only at more elevated drug concentrations if
compared to controls containing only PHA (4.0460.07) (p,0.001,
for both C2 and C3). On the other hand, when antituberculous
drugs were used at concentrations which are compatible with
those achieved in the serum of treated patients (C1), the
concentrations of IFN-c were not significantly different from
controls (p=0.071). No evidence of toxic effect of the combined
drugs on the cellular survival was found (data not shown).
Discussion
In recent years, a number of studies have been conducted to
investigate the impact of antituberculous treatment on specific
IFN-c response as measured by QFT-G assay. The analysis of the
literature data has shown controversial results in the case of both
latent and active TB treatment. Indeed, some authors have
demonstrated that IFN-c response to specific mycobacterial
antigens decreased or became negative [15–19], while others
have reported persistently positive or even stronger responses
during and after anti-TB treatment [20–25]. It has been suggested
that the progressive decline of IFN-c response measured by QFT-
G test reflects the reduction of mycobacterial burden following a
successful antituberculous treatment. However, it is unclear if the
persistence of IFN-c responses detected in IGRA assay will be
predictive of clinical and microbiological treatment failure or
relapse.
The present longitudinal study was designed to evaluate the
impact of antituberculous treatment on IFN-c response in patients
with active TB who were followed-up for 6 months before and at
completion of therapy. In agreement with our previous results, the
QFT-G assay showed an excellent degree of sensitivity and
specificity for diagnosis of active TB in our selected patients [31].
In addition, the concentrations of IFN-c were below the detection
threshold of the ex vivo QFT-G in all healthy unexposed
individuals with no history of TB and no know TB contact.
The longitudinal analysis by QFT-G assay showed that in the
majority of our TB patients there was a correlation between
clinical treatment outcome and changes of IFN-c response to M.
tuberculosis-specific antigens. Indeed, for all patients who had a
complete resolution of clinical disease and whose microbiological
culture results were negative for M. tuberculosis at 6-month
treatment completion, a progressive decline of IFN-c release was
seen and the baseline positive QFT-G result had turned negative.
Table 3. Characteristics of 5 TB subjects with persistent positive IGRA results and less good outcome.
Patients
Time of relapse after treatment
completion Drug resistance Ultimate clinical outcome
1 10 weeks INH+RIF Cured after 12 months of therapy
2 8 weeks INH Lost at follow-up
3 8 weeks INH+RIF Cured after 12 months of therapy
4 4 weeks ND Disseminated disease
5 6 weeks INH+RIF Cured after 9 months of therapy
Abbreviations:
ND: not done; INH : Isoniazid; RIF: rifampicin.
doi:10.1371/journal.pone.0005187.t003
Table 4. IFN-c responses to mycobacterial antigens, PPD and
PHA assessed by short or prolonged incubation-based assays.
Patients Median IFN-c release in UI/mL (range) P value
Incubation time
18 h
Incubation time 6
days
Group A (n=8)
rESAT-6/rCFP-10 0 (0–0,83) 0,015 (0–0,19) 0,625
PPD 0,865 (0–8,3) 7,2 (0,04–8,29) 0,033
PHA 2,65 (0,21–8,25) 8,55 (2.19–16,93) 0,6
Group B (n=10)
rESAT-6/rCFP-10 2,5 (0,02–7) 6,69 (2,17–17,95) 0,004
PPD 5,16 (0,43–18,21) 8,44 (5,19–18,55) 0,005
PHA 7,39 (1,16–19,76) 9,19 (1,08–20,1) 0,5
Healthy controls (n=5)
rESAT-6/rCFP-10 0 (0–0,36) 0 (0–0,05) 0,211
PPD 0,15 (0,1–0,44) 0,29 (0,15–0,51) 0,078
PHA 6,05 (1,05–8,05) 8,27 (0,3–8,89) 0,5
Abbreviations:
PPD: purified protein derivative; PHA: phytohemagglutinin; rESAT-6:
recombinant ESAT-6; rCFP-10: recombinant CFP-10.
Group A: TB patients who had a QFT-G reversion (positive to negative) at the
end of therapy.
Group B: TB patients who remained QFT-G positive at the end of therapy.
doi:10.1371/journal.pone.0005187.t004
Anti-TB Drugs and IFN-c Assay
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reported a progressive decrease in the frequency of M. tuberculosis
antigen-specific IFN-c-secreting T cells after successful treatment
for active TB [15–19,32]. In a recent study in Gambia, a
significant proportion of patients who successfully completed a
course of standard TB treatment changed from a positive to a
negative IGRA after 12 months after their initial diagnosis [18].
Similarly, in Cape Town, 81% HIV-negative patients who had
successfully completed TB treatment were IGRA negative [19]. It
has been suggested that negative IFN-c release assay results after
treatment of active TB indicates successful antibiotic-induced
killing of all bacilli.
We have also shown that, in the patients with successful
treatment for active TB, the release of IFN-c is absent even after a
prolonged 6-day incubation with both ESAT-6 and CFP-10
antigens. It has been suggested that IGRAs based on a prolonged
period of incubation with mycobacterial antigens could detect
response of central memory T-cells [24] and are more sensitive to
identify past latent TB infection; on the other hand, short-
incubation IGRAs mainly detect circulating effector memory T
cells whose numbers correlate with recent or ongoing active M.
tuberculosis infection [33]. Our results showed that the percentage of
both CD4+ and CD8+ T-cells EM phenotype was markedly lower
in the patients whose baseline positive QFT-G result had turned
negative at treatment completion. The overall low percentage of T
cells with EM phenotype and the progressive disappearance of
IFN-c responses after both short and prolonged stimulation with
rRD1 proteins may be consistent with cessation of antigen
stimulation in vivo and the clearance of viable bacilli. In the
present study, we did not measure the separate IFN-c responses to
ESAT-6 and CFP-10 antigens, although recent findings suggest
that quantitative response to CFP-10 only antigen may be a more
useful monitoring marker of clinical efficacy for active TB disease
treatment [34,35].
Figure 2. Evaluation of individual IFN-c production by prolonged-based incubation assay. Response to sum of intact recombinant ESAT-
6 and CFP-10 proteins after 6 days of stimulation was evaluated in 8 TB patients with QFT-G reversion (positive to negative) during treatment (A), 10
TB patients with persistent QFT-G positive results at the end of therapy (B), and 5 healthy donors (C). The largest increase in IFN-c production was
seen only in TB patients with persistent positive QFT-G results. Statistical significance was analyzed by the Mann–Whitney U-test.
doi:10.1371/journal.pone.0005187.g002
Table 5. Percentage of CD4+ and CD8+ T cells with effector/
memory and central/memory phenotype in 18 TB patients at
treatment completion.
Patients P value
Group A (n=8) Group B (n=10)
CD4+ T cells
TEM% (range) 21,27 (2,61–27,1) 41,7 (12,36–52,65) 0,001
TCM% (range) 2,36 (1,69–15,9) 15,82 (11,25–28,39) 0,003
CD8+ T cells
TEM% (range) 11,2 (5,6–21,4) 18,55 (12,5–35,6) 0,036
TCM% (range) 9,9 (3,1–14) 14 (6,7–22) 0,087
Abbreviations:
TEM: T cells with an effector/memory phenotype, defined as CD45RO+/CCR72.
TCM: T cells with central/memory phenotype, defined as CD45RO+/CCR7+.
Group A: TB patients who had a QFT-G reversion (positive to negative) at the
end of therapy.
Group B: TB patients who remained QFT-G positive at the end of therapy.
doi:10.1371/journal.pone.0005187.t005
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could be due to a direct inhibitory effect of antituberculous
drugs, cells were incubated in vitro with serial concentrations of
INH, RIF, ETB and PZA. We demonstrated for the first time
that the four antituberculous drugs did not exert any down-
regulatory effect on IFN-c production within the range of
therapeutically achievable concentrations. Preliminary works
suggest that reversions of IGRA from positive to negative results
can occur with serial testing [36]; moreover, T cell responses,
especially weakly positive responses, tend to fluctuate over time,
even in the absence of specific treatment [37–40]. Although the
present study was not designed to evaluate the reproducibility of
the QFT-G assay, we demonstrated no significant variations in
IFN-c concentrations over time in a group of healthy unexposed
individuals with any history of TB and no know TB contact.
Overall, these findings suggest that the decrease of IFN-c
response to mycobacterial antigens in patients with successful
treatment response is not due to a direct inhibitory of
antituberculous drugs or to the variability of the IGRA, but it
likely reflects the reduction in bacterial burden.
Figure 3. Cytofluorimetric analysis of phenotypic profile of T cells from two representative TB patients at the end of treatment. A
representative sample of one TB patient with QFT-G reversion (positive to negative) at the end of therapy (panel A) and one TB patient with
persistent QFT-G positive result (panel B) is shown. The percentage of CD4+ and CD8+ T cells that expressed CD45RO and lymphotropic chemokine
receptor CCR7 was assessed in diluted whole blood after 6 days of in vitro stimulation with intact recombinant ESAT-6 and CFP-10 proteins. Effector
memory (EM) cells (CD45RO+/CCR72) are shown in the upper left quadrants of both panels; central/memory (CM) cells (CD45RO+/CCR7+) are
showed in the upper right quadrants of both panels.
doi:10.1371/journal.pone.0005187.g003
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G assay despite active TB disease treatment. Increased IFN-c
response was also maintained by using a whole blood IGRA based
on a prolonged 6-day in vitro stimulation with mycobacterial
antigens. In these patients with persistent positive response on
QFT-G assay most CD4+ T-cells had an EM phenotype. In one
recent study, Katyar et al. suggested that a higher IFN-c response
at 2 months could be an independent indicator of the likelihood of
remaining sputum culture-positive at the end of the intensive
phase of anti-tuberculosis treatment [32]. In another study,
Carrara et al. suggested that a delayed drop in TB IFN-c release
could be an indicator of adverse outcome and poor response to
treatment [17]. In the present study, 5 of the 11 patients with
persistent positive IGRA response did not respond to the 6-month
treatment course, whereas the remaining six patients had clinical
and microbiological response to treatment. The reasons for the
persistence of increased IFN-c response in spite of a successful
treatment for active TB are not yet established. Since our patients
come from a country with low TB incidence (Italy), it is reasonable
to rule out a possible continued exposure to M. tuberculosis. On the
other hand, we cannot exclude potential exposure to environ-
mental mycobacteria, as well as persistent T-cell response in the
presence of low antigen stimulation or genetic polymorphisms in
the host.
In conclusions, the present study suggests that the decrease in
the M. tuberculosis-specific T cells responses following successful
anti-TB therapy may have a clinical value as a supplemental tool
for the monitoring of the efficacy of pharmacologic intervention
for active TB. In addition, the antituberculous drugs do not have
any direct effect on host immune response. Investigations on T-cell
kinetics and functions are needed to better investigate the
significance of the persistent IGRA positive results which are not
predictive of a negative clinical outcome and poor response to
treatment.
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